Compare LCUT & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCUT | RNA |
|---|---|---|
| Founded | 1945 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.1M | 222.5M |
| IPO Year | 1996 | 2025 |
| Metric | LCUT | RNA |
|---|---|---|
| Price | $8.76 | $12.13 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 20 |
| Target Price | $5.00 | ★ $69.26 |
| AVG Volume (30 Days) | ★ 241.6K | 229.2K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $647,933,000.00 | N/A |
| Revenue This Year | $3.74 | $88.12 |
| Revenue Next Year | $1.20 | $18.11 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.90 | $11.40 |
| 52 Week High | $9.80 | $73.06 |
| Indicator | LCUT | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 54.62 | 39.63 |
| Support Level | $7.57 | $11.40 |
| Resistance Level | $9.61 | $14.05 |
| Average True Range (ATR) | 0.67 | 0.53 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 66.32 | 10.70 |
Lifetime Brands Inc is a U.S.-based company that designs, sources, and sells branded kitchenware, tableware, and other home solution products used in the home. The company's product portfolio comprises kitchen tools, cutlery, thermometers, cutting boards, spice racks, dinnerware, stemware, flatware, bath scales, thermal beverage ware, food storage, neoprene travel products, etc. These products are marketed under owned or licensed brands like Farberware, KitchenAid, Mikasa, Misto, Taylor, Sabatier, and Pfaltzgraff, among others. The company mainly sells its products directly to retailers and distributors, and a limited selection directly to consumers through its own websites. It has two reportable operating segments: U.S., which derives maximum revenue, and International.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.